Recent Updates
Recently added Catalysts
BLCO Positive Sentiment

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

Friday, September 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bausch + Lomb has announced that its SeeLyra femtosecond laser has received CE Mark approval in Europe. This next-generation device is noted for its compact design and aims to enhance precision and control during various eye surgeries, including cataract and LASIK procedures. The approval marks a significant milestone for the company in expanding its product offerings in the eye health sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bausch + Lomb received CE Mark approval for SeeLyra.
  • SeeLyra is a compact femtosecond laser platform.
  • The device enhances precision and control for surgeons.
  • It is designed for various eye surgeries, improving patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Lead asset
Mapracorat
Phase 3 · Cataract

Full Press Release Details

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously

Frequently Asked Questions

What is the SeeLyra femtosecond laser?

SeeLyra is a next-generation femtosecond laser designed for eye surgeries.

What approvals has SeeLyra received?

SeeLyra has received CE Mark approval for use in Europe.

What types of surgeries can SeeLyra assist with?

It is used for cataract, LASIK flap, and corneal therapeutic surgeries.

What are the benefits of the SeeLyra laser?

The laser offers surgeons enhanced precision and control during procedures.

ShareAdd on Google
Tags: BLCO Viatris Investor Conferences Healthcare Bausch + Lomb SeeLyra CE Mark femtosecond laser eye health
Last updated: Sep 11, 2026

Biotech snapshot

Cash runway
$378M liquidity · $0M/mo burn
Low dilution risk
Lead asset
MapracoratPhase 3
Cataract →

Catalyst track record

+13%
best trade around BLCO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for BLCO.

See every catalyst's timing & PoA →